Artificial intelligence is reshaping the drug discovery and development process, offering unprecedented opportunities to create safer, more effective therapies at a fraction of the time and cost of traditional methods. This session will delve into how cutting-edge AI technologies are optimizing every stage of the pharmaceutical pipeline, from novel target identification to molecule design and clinical trial optimization.

The discussion will focus on the real-world application of AI-driven tools, including generative AI and large language models, in accelerating drug development. Participants will learn how these technologies are being used today to identify novel therapeutic candidates, generate innovative drug-like molecules, and predict clinical outcomes with remarkable accuracy. The session will also provide insights into emerging AI technologies still in development and their potential to further enhance precision and scalability in the pharmaceutical industry.

Beyond drug development, AI is driving advancements in aging research, longevity science, and sustainability initiatives. By uncovering biological mechanisms of aging and identifying therapeutic targets, AI is contributing to interventions that extend healthspan and address age-related diseases. Additionally, AI is being leveraged to develop more sustainable drug development approaches that reduce environmental impact while maintaining efficiency and scalability.

This session is designed for healthcare professionals, researchers, industry leaders, and anyone interested in learning more about artificial intelligence in early drug discovery. The speaker will provide a comprehensive understanding of the current and future landscape of AI-powered innovation in healthcare by connecting the latest advancements in artificial intelligence with practical applications across drug discovery, longevity research, and sustainability.